1. <th id="ulteb"></th>
      <tr id="ulteb"></tr>

        <strike id="ulteb"></strike>
      1. <thead id="ulteb"><option id="ulteb"></option></thead>
          服務熱線: +86-0571-28908600     加入收藏 | 在線留言
        新聞中心
        聯系我們
        總機:
        +86 571 28901357
        郵箱:
        PR@aceabio.com.cn
        工作時間:
        星期一 ~ 星期五
        聚集WCLC 2016·入圍WCLC 2016口頭報告的中國研究早知道!

        round_corner_image_by_atool-56.png


        奧地利當地時間12月3日~7日,2016年國際肺癌研究學會(IASLC)年會暨第17屆世界肺癌大會(WCLC)將在奧地利維也納如期舉行。今年,《中國醫學論壇報》編輯,帶著對會議內容的期待,和與會的專家一起為您帶來大會最新、最熱最有價值的肺癌研究、新聞及資訊。敬請關注《中國醫學論壇報》專題系列報道。


        本次大會中,中國大陸、臺灣及香港地區共計34項研究入圍了口頭報告,其中,廣東省人民醫院、廣東省肺癌研究所吳一龍教授的研究“BRAIN: A Phase – Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)”更入選了大會的主席研討會,充分展現了我國原創研究的力量與風采。除了這些入選口頭報告的研究,我國肺癌領域的多位專家學者也受邀在大會的諸多環節發表演說、分享經驗,都非常值得期待?!吨袊t學論壇報》編輯根據目前已發布的日程,將入選大會口頭報告(oral session,mini oral session)的研究進行了梳理,以饗讀者。


        12月3日

        WARDROBE OPEN

        Foyer D

        Exit U2 Station ‘Krieau’

        • 13:30 WS02.16: The Shanghai Screening Trial

          Liu Shi-Yuan, China

        12月4日

        Joint IASLC – Chinese Society for Clinical Oncology – Chinese Alliance Against Lung Cancer Session

        ROOM: STOLZ 1

        • 08:30 JCES01.03: Perspectives on Precision Medicine for Early Stage NSCLC

          Jie Hu, Zhongshan Hospital Fudan University, China

        • 08:50 JCES01.04: Liquid Biopsy in Monitoring Dynamic Changes of Driver Genes in Advanced NSCLC

          Qing Zhou, Guangdong Lung Cancer Institute; Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, China

        • 09:10 JCES01.05: New Clinical Trials on Gene Alteration in China

          Shun Lu, Shanghai Chest Hospital, Jiao Tong University, China

        • 10:30 JCES01.09: A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR–TKI Resistance

          Wenxian Wang, Zhejiang Cancer Hospital, China

        • 10:40 JCES01.10: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer

          Yue Zhao, Fudan University Shanghai Cancer Center,China

        • 10:50 JCES01.11: Altered Expression of Programmed Death–Ligand 1 after Neo–Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma

          Zhengbo Song, Zhejiang Cancer Hospital, China

        12月5日

        OA07: Lymph Node Metastases and Other Prognostic Factors for Local Spread

        ROOM: STOLZ 1

        • 14:30 OA07.02: Omitting Intrapulmonary Lymph Node Retrieval May Affect the Oncological Outcome of pN0 Lung Cancer Patients: A Propensity Score Match Analysis

          Nan Wu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

        OA08: Targeted Therapies in Brain Metastases

        ROOM: SCHUBERT 1, LEVEL ONE

        • 16:00 OA08.01: Exploration of the Underlying Mechanisms of Leptomeningeal Metastasis in NSCLC Patients through NGS of Cerebrospinal Fluid

          Yun Fan, Zhejiang Cancer Hospital, China

        MA02: RNA in Lung Cancer

        ROOM: STOLZ 2

        • 15:14 MA02.07: Evaluation of Exosomal miRNAs from Plasma as Potential Biomarker for NSCLC

          Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

        MA03: Epidemiology, Risk Factors and Screening

        ROOM: LEHAR 3–4

        • 14:32 MA03.03: High Risk for Second Primary Lung Cancer in Taiwanese Early–Onset Female Breast Cancer Patients

          Pei–Ying Lin, National Taiwan University Hospital,Taiwan

        MA04: HER2, P53, KRAS and Other Targets in Advanced NSCLC

        ROOM: LEHAR 3–4

        • 16:12 MA04.03: Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC

          Shengxiang Ren, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, China

        MA06: Locally Advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices

        ROOM: STRAUSS 2

        • 16:36 MA06.06: Tumor Microenvironment and Brain Metastases in Completely Resected Stage IIIA(N2) Non Small Cell Lung Cancer

          Qin Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

        MA05: Innovative Techniques in Pulmonology and the Impact on Lung Cancer

        ROOM: STRAUSS 1

        • 17:00 MA05.09: There is a Closely Relation between Exhaled Nitric Oxide and Radiation Pneumonitis

          Jiancheng Li, Fujian Cancer Hospital, China

        12月6日

        PL03: Presidential Symposium

        ROOM: HALL D (PLENARY HALL)

        • 09:25 PL03.05: BRAIN: A Phase – Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)

          Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academyof Medical Sciences, China

        OA09: Locally Advanced NSCLC:Innovative Treatment Strategies

        ROOM: STRAUSS 3

        • 11:20 OA09.03: Randomized Controlled Study Comparing Adjuvant versus Neo–Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC

          Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

        • 12:05 OA09.07: Individual Isotoxic RT Dose Escalation Based on V20 and Advanced? Technologies Benefit Stage NSCLC Treated with CCRT

          Baosheng Li, Shandong Cancer Hospital, China

        OA11: Angiogenesis in Advanced Lung Cancer

        ROOM: STOLZ 2

        • 11:20 OA11.03: A Randomized, Multi–Center, Double–Blind Phase II Study of Fruquintinib in Patients with Advanced Non–Small Cell Lung Cancer

          Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

        • 12:05 OA11.07: Combining Anti–Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer

          Sha Zhao, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine,China

        OA12: SBRT and Other Issues in Early Stage NSCLC

        ROOM: STRAUSS 2

        • 11:45 OA12.05: Noninvasive CT–Based Image Biopsy System (iBiopsy) for Early Stage Lung Adenocarcinoma

          Dawei Yang, Zhongshan Hospital Fudan University, China

        MA08: Treatment Monitoring in Advanced NSCLC

        ROOM: LEHAR 3–4

        • 11:12 MA08.03: Osimertinib vs Platinum–Pemetrexed for T790M–Mutation Positive Advanced NSCLC (AURA3):Plasma ctDNA Analysis

          Yi Long Wu, Guangdong Lung Cancer Institute,Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

        • 11:30 MA08.05: Depth of Response to First–Line EGFR TKI Does Not Predict Survival in EGFR–Mutated NSCLC Patients

          Ting–Hui Wu, National Taiwan University Hospital,Taiwan

        • 11:42 MA08.07: Prospective Sequential Counts of Total CTC or cKIT+CTC in Advanced NSCLC with 1st Line Chemotherapy (POLICE)

          Yi Long Wu, Guangdong Lung Cancer Institute,Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

        MA10: Facing the Real World: New Staging System and Response Evaluation in Immunotherapy

        ROOM: STOLZ 2

        • 14:20 MA10.01: Validations of the 8th AJCC/UICC Lung Cancer Staging System in a Large North America Cohort

          Lin Yang, Cancer Hospital,Chinese Academy of Medical Sciences, China

        MA11: Novel Approaches in SCLC and Neuroendocrine Tumors

        ROOM: STRAUSS 3

        • 14:20 MA11.01: Molecular Profiling of Large Cell Neuroendocrine Carcinoma Using Capture–Based Targeted Sequencing

          Zhen Zhou, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

        • 15:20 MA11.09: Progastrin–Releasing Peptide (ProGRP) to Rule out Progressive Disease in Patients with Small Cell Lung Carcinoma (SCLC)

          Xiaotong Zhang, Peking Union Medical College Hospital (PUMCH), China

        12月7日

        OA19: Translational Research in Early Stage NSCLC

        ROOM: SCHUBERT 3

        • 11:20 OA19.03: Identify Lung Adenocarcinoma in Situ Among Pulmonary Micro–Nodules Through Blood Gene Expression Profiles

          Baohui Han, Shanghai Chest Hospital, China

        OA21: Palliative and Supportive Care for Lung Cancer Patients

        ROOM: SCHUBERT 5

        • 11:00 OA21.01: Pooled Analysis of the Incidence and Risk of Treatment–Related Pneumonitis with Anti–PD–1/PD–L1 Therapies in Cancer Patients

          Shaodong Hong, Sun Yat–sen University Cancer Center,China

        MA15: Immunotherapy Prediction

        ROOM: SCHUBERT 1, LEVEL ONE

        • 14:32 MA15.03: The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD–1 Blockade in Advanced NSCLC

          Weijing Cai, Shanghai Pulmonary Hospital, China

        • 15:26 MA15.10: Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD–1 Blockade Immunotherapy in Lung Adenocarcinoma

          Zhong–Yi Dong, Guangdong Lung Cancer Institute,Guangdong General Hospital, China

        MA16: Novel Strategies in Targeted Therapy

        ROOM: STRAUSS 2

        • 14:56 MA16.06: Phase I/II Study of AC0010, Mutant–Selective EGFR Inhibitor, in Non–Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

          Yi Long Wu, Guangdong Lung Cancer Institute,Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, China

        MA17: Genetic Drivers

        ROOM: LEHAR 1–2

        • 14:32 MA17.03: Identifying Genomic Alteration and Inter–Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and ctDNA

          Kezhong Chen, Peking University People’s Hospital,China

        • 14:50 MA17.05: Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas

          Hao–ran Zhai, Guangdong Lung Cancer Institute,Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University, China

        • 15:32 MA17.11: Knockdown of Akt2 Suppresses Tumorigenesis and Raf1 Overexpression Offsets This Effect in Non–Small Cell Lung Cancer

          Shuang Zhao, Department of Respiratory Medicine,West China Hospital, Sichuan University, Chengdu610041, China., China



        文章來源:壹生APP

        1. <th id="ulteb"></th>
          <tr id="ulteb"></tr>

            <strike id="ulteb"></strike>
          1. <thead id="ulteb"><option id="ulteb"></option></thead>
            国产A级毛片_高清无码视频直接看_深夜A级毛片催精视频免费_被陌生男揉摸的我高潮了-有限公司